Literature DB >> 16377535

A new model to monitor the virological efficacy of antiretroviral treatment in resource-poor countries.

Robert Colebunders1, Kamya R Moses, John Laurence, Hasan M Shihab, Fred Semitala, Fred Lutwama, Sabrina Bakeera-Kitaka, Lut Lynen, Lisa Spacek, Steven J Reynolds, Thomas C Quinn, Brant Viner, Harriet Mayanja-Kizza.   

Abstract

Monitoring the efficacy of antiretroviral treatment in developing countries is difficult because these countries have few laboratory facilities to test viral load and drug resistance. Those that exist are faced with a shortage of trained staff, unreliable electricity supply, and costly reagents. Not only that, but most HIV patients in resource-poor countries do not have access to such testing. We propose a new model for monitoring antiretroviral treatment in resource-limited settings that uses patients' clinical and treatment history, adherence to treatment, and laboratory indices such as haemoglobin level and total lymphocyte count to identify virological treatment failure, and offers patients future treatment options. We believe that this model can make an accurate diagnosis of treatment failure in most patients. However, operational research is needed to assess whether this strategy works in practice.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16377535     DOI: 10.1016/S1473-3099(05)70327-3

Source DB:  PubMed          Journal:  Lancet Infect Dis        ISSN: 1473-3099            Impact factor:   25.071


  23 in total

1.  Changes to antiretroviral drug regimens during integrated TB-HIV treatment: results of the SAPiT trial.

Authors:  Anushka Naidoo; Kogieleum Naidoo; Nonhlanhla Yende-Zuma; Tanuja N Gengiah; Nesri Padayatchi; Andrew L Gray; Sheila Bamber; Gonasagrie Nair; Salim S Abdool Karim
Journal:  Antivir Ther       Date:  2013-10-31

2.  Short communication: prospective comparison of qualitative versus quantitative polymerase chain reaction for monitoring virologic treatment failure in HIV-infected patients.

Authors:  Su Jin Jeong; Min Hyung Kim; Je Eun Song; Jin Young Ahn; Sun Bean Kim; Hea Won Ann; Jae Kyung Kim; Heun Choi; Nam Su Ku; Sang Hoon Han; June Myung Kim; Davey M Smith; Hyon-Suk Kim; Jun Yong Choi
Journal:  AIDS Res Hum Retroviruses       Date:  2014-05-15       Impact factor: 2.205

3.  Super Learner Analysis of Electronic Adherence Data Improves Viral Prediction and May Provide Strategies for Selective HIV RNA Monitoring.

Authors:  Maya L Petersen; Erin LeDell; Joshua Schwab; Varada Sarovar; Robert Gross; Nancy Reynolds; Jessica E Haberer; Kathy Goggin; Carol Golin; Julia Arnsten; Marc I Rosen; Robert H Remien; David Etoori; Ira B Wilson; Jane M Simoni; Judith A Erlen; Mark J van der Laan; Honghu Liu; David R Bangsberg
Journal:  J Acquir Immune Defic Syndr       Date:  2015-05-01       Impact factor: 3.731

4.  Determinants of Weight Evolution Among HIV-Positive Patients Initiating Antiretroviral Treatment in Low-Resource Settings.

Authors:  Diana Huisin ʼt Veld; Eric Balestre; Jozefien Buyze; Joris Menten; Antoine Jaquet; David A Cooper; Francois Dabis; Constantin T Yiannoutsos; Lameck Diero; Portia Mutevedzi; Matthew P Fox; Eugene Messou; Christopher J Hoffmann; Hans W Prozesky; Matthias Egger; Jennifer J Hemingway-Foday; Robert Colebunders
Journal:  J Acquir Immune Defic Syndr       Date:  2015-10-01       Impact factor: 3.731

5.  Antiretroviral therapy optimisation without genotype resistance testing: a perspective on treatment history based models.

Authors:  Mattia C F Prosperi; Michal Rosen-Zvi; André Altmann; Maurizio Zazzi; Simona Di Giambenedetto; Rolf Kaiser; Eugen Schülter; Daniel Struck; Peter Sloot; David A van de Vijver; Anne-Mieke Vandamme; Anders Sönnerborg
Journal:  PLoS One       Date:  2010-10-29       Impact factor: 3.240

6.  Response to zidovudine/didanosine-containing combination antiretroviral therapy among HIV-1 subtype C-infected adults in Botswana: two-year outcomes from a randomized clinical trial.

Authors:  Hermann Bussmann; C William Wester; Ann Thomas; Vladimir Novitsky; Reginald Okezie; Tanaka Muzenda; Tendani Gaolathe; Ndwapi Ndwapi; Norah Mawoko; Erik Widenfelt; Sikhulile Moyo; Rosemary Musonda; Madisa Mine; Joseph Makhema; Howard Moffat; Max Essex; Victor Degruttola; Richard G Marlink
Journal:  J Acquir Immune Defic Syndr       Date:  2009-05-01       Impact factor: 3.731

7.  Effectiveness of highly active antiretroviral therapy administered by general practitioners in rural South Africa.

Authors:  R E Barth; J T M van der Meer; A I M Hoepelman; P A Schrooders; D A van de Vijver; S P M Geelen; H A Tempelman
Journal:  Eur J Clin Microbiol Infect Dis       Date:  2008-07-16       Impact factor: 3.267

8.  Absolute CD4+ T-lymphocyte count as a surrogate marker of pediatric human immunodeficiency virus disease progression.

Authors:  Elijah Paintsil; Musie Ghebremichael; Sostena Romano; Warren A Andiman
Journal:  Pediatr Infect Dis J       Date:  2008-07       Impact factor: 2.129

9.  Comparative evaluation of the ExaVir Load version 3 reverse transcriptase assay for measurement of human immunodeficiency virus type 1 plasma load.

Authors:  Wendy Labbett; Ana Garcia-Diaz; Zoe Fox; Gillian S Clewley; Thomas Fernandez; Margaret Johnson; Anna Maria Geretti
Journal:  J Clin Microbiol       Date:  2009-08-05       Impact factor: 5.948

10.  The use of pooled viral load testing to identify antiretroviral treatment failure.

Authors:  Davey M Smith; Susanne J May; Josué Pérez-Santiago; Matthew C Strain; Caroline C Ignacio; Richard H Haubrich; Douglas D Richman; Constance A Benson; Susan J Little
Journal:  AIDS       Date:  2009-10-23       Impact factor: 4.177

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.